Metabolic
Retatrutide (RETA Peptide)
Explore Retatrutide 40mg in Peptide Pen format from Purita. Built around research quality and practical handling. Clear specifications and transparent product details make choosing and ordering straightforward.
€289.90 · 40mg
Available options
Product information
What it is Retatrutide (LY3437943) is a synthetic peptide with activity at GIP, GLP-1 and glucagon receptors. Having three targets is what makes the molecule different from the more familiar single and dual receptor agonists. GIP and GLP-1 are both incretin hormones. They are involved in glucose-dependent insulin signaling, although their effects are not identical. Glucagon takes the research in another direction. Its signaling is connected with hepatic glucose and lipid metabolism and with energy expenditure. Retatrutide puts these three receptor targets together, while compoundssuch as tirzepatide act at GIP and GLP-1 receptors. Research has looked beyond body weight Body weight has received plenty of attention in retatrutide research, but it is only one of the measurements researchers have followed. Clinical studies have also included waist circumference, HbA1c, fasting glucose, insulin and lipid levels. One Phase 2 trial looked at body-weight changes in adults with obesity or overweight without diabetes. It followed 338 participants for 48 weeks and included several retatrutide dose groups. The amount used made a difference. By week 48, mean body-weight reduction was 17.1% in the 4mg group and 22.8% in the combined 8mg group. The 12mg group reached 24.2%. For comparison, the reduction with placebo was 2.1%. Another Phase 2 trial